New boss takes reins at pet product firm
A YORK business specialising in supplying veterinary products has announced its chief executive is to step down as it reveals a “strong start” to the year.
In a trading update for the six months ending June 30, Animalcare Group said revenues rose more than six per cent from same period last year, up to £47.8 million.
The pharmaceutical division of the business saw revenues increase by 6.7 per cent from £33.1 million to £35.4 million, attributing the growth to “a stronger products mix”.
The firm, which acquired Belgium-based Ecuphar in July last year via a reverse takeover, also revealed that its current chief executive Chris Cardon, would step down to take on the role of chief strategy officer from October 1.
Jenny Winter will become Animalcare Group’s new CEO, bringing with her more than 20 years experience working in big pharma in various senior management and commercial roles for AstraZeneca and GlaxoSmithKline.
As chief strategy officer, Mr Cardon will continue to lead the company’s international strategic vision and acquisition strategy and be part of Ms Winter’s leadership team.
Jan Boone, chairman of Animalcare Group plc, said: “We are excited to welcome Jenny Winter, whose strong and varied international experience make her ideally placed to continue to realise the full benefits of the recent reverse merger and continue to implement our clear strategy for growth in the attractive animal health market.
“The Board would like to thank Chris for his significant achievements as chief executive, overseeing the transformational merger with Ecuphar and the transition of Animalcare to an international animal health business.
“His extensive experience will continue to be invaluable to the company in his new role and will be vital in the company’s plans for growth.”
Ms Winter added: “I am delighted to be joining Animalcare at a very exciting time for the company.
“My focus will be on accelerating the strong foundation for growth that has been already laid by the board and management team, focusing on consolidation, product development and maximising the potential of the group’s unique and highly compelling animal health portfolio.”
Mr Cardon said: “I am proud to have led Animalcare through a very significant period of development.